Dr. Drilon on MET-Amplified Lung Cancer

Alexander Drilon, MD
Published: Tuesday, Oct 24, 2017



Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of MET in patients with lung cancer.

Many drugs, such as antibodies or tyrosine kinase inhibitors (TKIs), have been developed to target MET, states Drilon. There are specific biomarker states that are drivers of the tumors, the first being MET exon 14 splicing mutations. They are the increased expression of the MET receptor on the cell surface.

A second biomarker state is highly MET-amplified lung cancers. For both biomarkers, there is data suggesting that these tumors respond well to targeted therapy, states Drilon.
 


Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of MET in patients with lung cancer.

Many drugs, such as antibodies or tyrosine kinase inhibitors (TKIs), have been developed to target MET, states Drilon. There are specific biomarker states that are drivers of the tumors, the first being MET exon 14 splicing mutations. They are the increased expression of the MET receptor on the cell surface.

A second biomarker state is highly MET-amplified lung cancers. For both biomarkers, there is data suggesting that these tumors respond well to targeted therapy, states Drilon.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x